These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 9379515)

  • 1. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
    Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
    Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
    Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
    J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time.
    Akimoto S; Masai M; Akakura K; Shimazaki J
    Eur Urol; 1995; 27(3):207-12. PubMed ID: 7541360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic factors for PSA relapse of prostate cancer after endocrine therapy].
    Nakata S; Nakano K; Takahashi H; Shimizu K; Kawashima K
    Nihon Hinyokika Gakkai Zasshi; 2005 Nov; 96(7):685-90. PubMed ID: 16363654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Determination of tumor marker doubling time in the patients with prostate cancer relapsed from endocrine therapy].
    Akimoto S; Masai M; Kitagawa N; Nakamura T; Shimazaki J
    Nihon Hinyokika Gakkai Zasshi; 1993 Mar; 84(3):450-6. PubMed ID: 7685840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group.
    Mulders PF; Dijkman GA; Fernandez del Moral P; Theeuwes AG; Debruyne FM
    Cancer; 1990 Jun; 65(12):2758-61. PubMed ID: 2187588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of the serum levels of bone formation and bone resorption markers in prostate cancer patients with bone metastasis.
    Akimoto S; Inomiya H; Furuya Y; Akakura K; Ito H
    Eur Urol; 1998 Aug; 34(2):142-7. PubMed ID: 9693250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
    Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
    Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer.
    Furuya Y; Nagakawa O; Fuse H
    Urol Int; 2003; 70(3):195-9. PubMed ID: 12660456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
    Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
    Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
    Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
    Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
    Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
    Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
    Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine variations in patients with hormone treated prostate cancer.
    Wise GJ; Marella VK; Talluri G; Shirazian D
    J Urol; 2000 Sep; 164(3 Pt 1):722-5. PubMed ID: 10953133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy for endocrine-therapy-refractory prostate cancer.
    Akimoto S; Ohki T; Akakura K; Masai M; Shimazaki J
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S18-22. PubMed ID: 7527733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress of endocrine therapy for prostate cancer and results].
    Kanetake H
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):413-7. PubMed ID: 8678491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.
    Hussain M; Wolf M; Marshall E; Crawford ED; Eisenberger M
    J Clin Oncol; 1994 Sep; 12(9):1868-75. PubMed ID: 8083710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).
    Bertagna C; De Géry A; Hucher M; François JP; Zanirato J
    Br J Urol; 1994 Apr; 73(4):396-402. PubMed ID: 8199827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma.
    Cipolla BG; Ziade J; Bansard JY; Moulinoux JP; Staerman F; Quemener V; Lobel B; Guillé F
    Cancer; 1996 Sep; 78(5):1055-65. PubMed ID: 8780544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.